CN102984938A - 轻度认知障碍(mci)和阿尔茨海默氏症的治疗方法 - Google Patents

轻度认知障碍(mci)和阿尔茨海默氏症的治疗方法 Download PDF

Info

Publication number
CN102984938A
CN102984938A CN2010800680043A CN201080068004A CN102984938A CN 102984938 A CN102984938 A CN 102984938A CN 2010800680043 A CN2010800680043 A CN 2010800680043A CN 201080068004 A CN201080068004 A CN 201080068004A CN 102984938 A CN102984938 A CN 102984938A
Authority
CN
China
Prior art keywords
nifedipine
approximately
described method
pharmaceutical composition
lactam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800680043A
Other languages
English (en)
Chinese (zh)
Inventor
M·洛弗尔
B·林恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
Original Assignee
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/034721 external-priority patent/WO2010132671A1/en
Application filed by University of Kentucky Research Foundation filed Critical University of Kentucky Research Foundation
Publication of CN102984938A publication Critical patent/CN102984938A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN2010800680043A 2010-05-13 2010-11-18 轻度认知障碍(mci)和阿尔茨海默氏症的治疗方法 Pending CN102984938A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2010/034721 2010-05-13
PCT/US2010/034721 WO2010132671A1 (en) 2009-05-15 2010-05-13 Treatment of mci and alzheimer's disease
PCT/US2010/057287 WO2011142778A1 (en) 2010-05-13 2010-11-18 Treatment of mci and alzheimer's disease

Publications (1)

Publication Number Publication Date
CN102984938A true CN102984938A (zh) 2013-03-20

Family

ID=44923820

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800680043A Pending CN102984938A (zh) 2010-05-13 2010-11-18 轻度认知障碍(mci)和阿尔茨海默氏症的治疗方法

Country Status (6)

Country Link
EP (1) EP2568811A4 (https=)
JP (1) JP2013526518A (https=)
CN (1) CN102984938A (https=)
AU (1) AU2010353287A1 (https=)
CA (1) CA2799162A1 (https=)
WO (1) WO2011142778A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106177046A (zh) * 2016-08-29 2016-12-07 杨添福 一种基于普立宁钾开发的神经认知障碍治疗药物及其制备方法
CN106636388A (zh) * 2016-12-15 2017-05-10 湖南中能荆卫生物科技有限公司 用于亨廷顿病诊断的基因及其应用以及由其编码的蛋白和蛋白的应用
CN106645505A (zh) * 2016-11-18 2017-05-10 中国医科大学 可实现glt‑1蛋白鉴定及绝对定量的试剂盒及测定方法
CN107022019A (zh) * 2016-11-24 2017-08-08 台州学院 一种用于脑内降铁除自由基的多肽、制备方法与应用
CN108191966A (zh) * 2018-01-11 2018-06-22 台州学院 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044737T2 (hu) * 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
SG11201510701QA (en) 2013-06-28 2016-01-28 Mcbi Inc Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
ES2693771T3 (es) * 2014-01-29 2018-12-13 Bristol-Myers Squibb Company Inhibidores de aril lactama quinasa
AU2020207203A1 (en) * 2019-01-07 2021-08-19 Cenna Biosciences Inc. Novel peptides and uses thereof
JP7321017B2 (ja) * 2019-07-17 2023-08-04 東海物産株式会社 機能性食品

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917832A (en) * 1971-05-28 1975-11-04 Merck Patent Gmbh Compositions comprising d-thyroxine and d-triiodothyronine
CN1479616A (zh) * 2000-11-21 2004-03-03 霍华德・齐克 使用1,4-二氢吡啶钙通道阻断剂治疗疱疹神经病毒病症
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8002A (en) * 1851-03-25 Upright pianoforte
CA2325353A1 (en) * 1998-04-08 1999-10-14 Oregon Health Sciences University Enhancement of cellular gallium uptake
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
CA2546395A1 (en) * 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors
PT1874311E (pt) * 2005-04-15 2011-11-25 Res & Innovation S P A Método para prevenir, retardar ou reverter a deposição anómala de amilóide
EP1955698B1 (en) * 2005-12-02 2013-10-30 Mochida Pharmaceutical Co., Ltd. Preventive/therapeutic agent for alzheimer's dementia
WO2008051291A2 (en) * 2006-04-11 2008-05-02 Ordway Research Institute Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
WO2008109613A1 (en) * 2007-03-05 2008-09-12 Wyeth Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors
WO2010034110A1 (en) * 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
TW201103907A (en) * 2009-03-20 2011-02-01 Lundbeck & Co As H Amide derivatives as neuropeptide Y5 receptor ligands

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917832A (en) * 1971-05-28 1975-11-04 Merck Patent Gmbh Compositions comprising d-thyroxine and d-triiodothyronine
CN1479616A (zh) * 2000-11-21 2004-03-03 霍华德・齐克 使用1,4-二氢吡啶钙通道阻断剂治疗疱疹神经病毒病症
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HENK DE VRIES ET AL.: "Photoreactivity of nifedipine in vitro and in vivo", 《JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY》, vol. 43, 31 December 1998 (1998-12-31), pages 218 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106177046A (zh) * 2016-08-29 2016-12-07 杨添福 一种基于普立宁钾开发的神经认知障碍治疗药物及其制备方法
CN106645505A (zh) * 2016-11-18 2017-05-10 中国医科大学 可实现glt‑1蛋白鉴定及绝对定量的试剂盒及测定方法
CN107022019A (zh) * 2016-11-24 2017-08-08 台州学院 一种用于脑内降铁除自由基的多肽、制备方法与应用
CN106636388A (zh) * 2016-12-15 2017-05-10 湖南中能荆卫生物科技有限公司 用于亨廷顿病诊断的基因及其应用以及由其编码的蛋白和蛋白的应用
CN108191966A (zh) * 2018-01-11 2018-06-22 台州学院 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽
CN108191966B (zh) * 2018-01-11 2020-10-27 桂林医学院 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽

Also Published As

Publication number Publication date
EP2568811A4 (en) 2014-03-12
EP2568811A1 (en) 2013-03-20
CA2799162A1 (en) 2011-11-17
WO2011142778A1 (en) 2011-11-17
JP2013526518A (ja) 2013-06-24
AU2010353287A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
CN102984938A (zh) 轻度认知障碍(mci)和阿尔茨海默氏症的治疗方法
US20100292281A1 (en) Treatment of mci and alzheimer's disease
Day et al. Ethanol exposure alters Alzheimer's-related pathology, behavior, and metabolism in APP/PS1 mice
AU2019382044B2 (en) Animal models, screening methods, and treatment methods for intraocular diseases or disorders
JP5933258B2 (ja) ゾニサミドおよびアカンプロセートを用いるアルツハイマー病および関連障害の処置のための併用組成物
JP2012526844A5 (https=)
KR20200103680A (ko) 치매를 포함하는 신경 장애에 대한 치료 조성물 및 방법
Sikora et al. Synaptic zinc contributes to motor and cognitive deficits in 6-hydroxydopamine mouse models of Parkinson's disease
ES2936833T3 (es) Tasimelteón para tratar síndrome de Smith-Magenis
US9968574B2 (en) Treatment of MCI and Alzheimer's disease
JP6918839B2 (ja) 概日時計の乱れに関連するマイクロバイオームの調節異常を処置するための方法及び医薬組成物
WO2020165802A1 (en) Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors
US20100247688A1 (en) Pirenzepine and derivatives thereof as anti-amyloid agents
JP2021520413A (ja) 眼科的状態のための療法
McKee Circadian protein BMAL1 regulates astrocyte activation and protein degradation in health and disease
Lovell et al. Treatment of MCI and Alzheimer's Disease
KR20250173974A (ko) 엠파글리플로진 및 텔미사르탄을 함유하는 대사이상 관련 지방성 간질환 예방 또는 치료용 약학적 조성물
ES2981295T3 (es) Composición para el tratamiento y prevención de trastornos neurodegenerativos
CN111601604A (zh) 人参皂苷m1用于治疗亨丁顿舞蹈症的用途
HK1145641A (en) Pirenzepine and derivatives thereof as anti-amyloid agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130320